---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017194"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:55:01.515569+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q1 net loss $57.7M; clonoSEQ volume up 57% YoY

## Summary
- Revenue $37.6M (-3% YoY); MRD $21.4M (+20%); Immune Medicine $16.2M (-22% due to Genentech amortization decline).
- clonoSEQ test volume 12,079 (+57% YoY); new Takeda pan-portfolio collaboration for MRD endpoint.
- Net loss $57.7M (vs $62.8M prior); Adjusted EBITDA loss $37.1M (vs $43.1M prior).
- FY2023 revenue guidance reaffirmed $205M-$215M; expects OpEx below FY2022 level of $385.5M.
- Consolidation of President and COO roles under Julie Rubinstein.

## SEC filing metadata
- accession: 0000950170-23-017194
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/0000950170-23-017194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/adpt-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017194
- JSON: https://secwatch.observer/filing/0000950170-23-017194.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017194.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported the quarter ended March 31, 2023 results: revenue $37.6 million, net income Net loss was $57.7 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2023
  - Revenue: $37.6 million
  - Net income: Net loss was $57.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: goals in both MRD and Immune Medicine and remain committed to drive operational efficiencies while managing capital allocation to support growth.” Recent Highlights • Revenue of $37.6 million for the first quarter 2023, representing a 3% decrease from $38.6 million in the first quarter 2022, which reflects the expected $3.2 million decline in amortization of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/0000950170-23-017194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.